Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SATURDAY STUDY: Abbreviated R-CHOP in Localized Gastrointestinal DLBCL
NCT03399747Phase 2Unknown
- Sponsor
- Asan Medical Center
- Start
- Dec 2016
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
01
Overview
A Phase 2 trial of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone in diffuse large B-cell lymphoma (DLBCL), sponsored by Asan Medical Center. Status: unknown.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisolone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03399747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03399747.